T7402

Paclitaxel

from Taxus brevifolia, ≥95% (HPLC), powder

• Formula empirica (notazione di Hill): C₄₇H₅₁NO₁₄
• Numero CAS: 33069-62-4
• Peso molecolare: 853.91
• Beilstein: 1420457
• Numero MDL: MFCD00869953
• Codice UNSPSC: 12161501
• ID PubChem: 24277878
• NACRES: NA.77

Proprietà

• Origine biologica: Taxus brevifolia
• Livello qualitativo: 200
• Saggio: ≥95% (HPLC)
• Forma fisica: powder
• Colore: white
• Punto di fusione: 213 °C (dec.) (lit.)
• Solubilità: DMSO: 50 mg/mL (can be stored frozen for several months); methanol: soluble 50 mg/mL, clear, colorless (undergoes transesterification); ethanol: soluble
• Spettro attività antibiotica: viruses
• Modalità d’azione: DNA synthesis | interferes
• Ideatore: Bristol-Myers Squibb
• Temperatura di conservazione: 2-8°C
• Stringa SMILE: [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7
• InChI: 1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1; RCINICONZNJXQF-MZXODVADSA-N
• Informazioni sul gene: human ... BCL2(596) , TUBA1A(7846) , TUBA1B(10376) , TUBA1C(84790) , TUBA3C(7278) , TUBA3E(112714) , TUBA4A(7277) , TUBB(203068) , TUBB1(81027) , TUBB2A(7280) , TUBB2B(347733) , TUBB3(10381) , TUBB4A(10382) , TUBB4B(10383) , TUBB6(84617) , TUBB8(347688)

Descrizione

Descrizione generale

Chemical structure: taxoide

Applicazioni

Paclitaxel has been used as a component of the dechorionation buffer for Gryllus bimaculatus eggs. Paclitaxel has also been used for studying its effect on the movement of all-trans retinoic acid (ATRA) differentiated NB4 cells.

Azioni biochim/fisiol

Paclitaxel is a potent anti-neoplastic and anti-mitotic taxane drug, which binds to the N-terminus of β-tubulin and and stabilizes microtubules arresting the cell cycle at the G2/M phase. The microtubule damage induces apoptosis through a JNK-dependent pathway followed by a JNK-independent pathway, perhaps related to the activation of protein kinase A (PKA) or of Raf-1 kinase, resulting in phosphorylation of Bcl-2. A major metabolite via CYP2CB is 6α-hydroxypaclitaxel (6α-OHP).

Caratteristiche e vantaggi

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Confezionamento

Bottomless glass bottle. Contents are inside inserted fused cone.

Avvertenza

Paclitaxel undergoes transesterification in methanol and hydrolyzes in aqueous solutions.

Nota sulla preparazione

Paclitaxel is soluble in methanol at 50 mg/ml and yields a clear, colorless solution. It is also soluble in DMSO (50 mg/ml) and ethanol.

Informazioni sulla sicurezza

• Pittogrammi: GHS08
• Avvertenze: Danger
• Indicazioni di pericolo: H341,H360FD,H371,H372
• Consigli di prudenza: P202 - P260 - P264 - P280 - P308 + P311 - P405
• Classi di pericolo: Muta. 2 - Repr. 1B - STOT RE 1 - STOT SE 2
• Organi bersaglio: Central nervous system,Bone marrow,Cardio-vascular system, Eyes,Central nervous system
• Codice della classe di stoccaggio: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe di pericolosità dell'acqua (WGK): WGK 3
• Punto d’infiammabilità (°F): Not applicable
• Punto d’infiammabilità (°C): Not applicable
• Dispositivi di protezione individuale: Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges